[go: up one dir, main page]

WO2014125408A3 - Dérivés de 1h-pyrrolopyridinone substitués en tant qu'inhibiteurs de kinase - Google Patents

Dérivés de 1h-pyrrolopyridinone substitués en tant qu'inhibiteurs de kinase Download PDF

Info

Publication number
WO2014125408A3
WO2014125408A3 PCT/IB2014/058881 IB2014058881W WO2014125408A3 WO 2014125408 A3 WO2014125408 A3 WO 2014125408A3 IB 2014058881 W IB2014058881 W IB 2014058881W WO 2014125408 A3 WO2014125408 A3 WO 2014125408A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
kinase inhibitors
substituted
disorder
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/058881
Other languages
English (en)
Other versions
WO2014125408A2 (fr
Inventor
Anima BORUAH
Srikanth CHITTY VENKATA
Subramanya Hosahalli
Sunil Kumar Panigrahi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurigene Oncology Ltd
Original Assignee
Aurigene Discovery Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Ltd filed Critical Aurigene Discovery Technologies Ltd
Publication of WO2014125408A2 publication Critical patent/WO2014125408A2/fr
Publication of WO2014125408A3 publication Critical patent/WO2014125408A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de 1H-pyrrolopyridinone substitués de formule (1) en tant qu'inhibiteurs de protéines kinases, dans laquelle R1, R2, R3, R4, R5, R6 et 'p' ont les significations proposées dans la spécification, et leurs sels pharmaceutiquement acceptables qui sont utiles dans le traitement et la prévention de maladies ou de troubles, en particulier leur utilisation dans des maladies ou des troubles pour lesquels l'inhibition d'une enzyme kinase est avantageuse, plus particulièrement l'inhibition de l'enzyme BTK. La présente invention concerne en outre des procédés de synthèse et d'administration des composés inhibiteurs de kinase. La présente invention concerne en outre des formulations pharmaceutiques comprenant au moins un composé inhibiteur de kinase conjointement à un vecteur, un diluant ou un excipient, pharmaceutiquement acceptables, pour celles-ci.
PCT/IB2014/058881 2013-02-12 2014-02-10 Dérivés de 1h-pyrrolopyridinone substitués en tant qu'inhibiteurs de kinase Ceased WO2014125408A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN598CH2013 2013-02-12
IN598/CHE/2013 2013-02-12

Publications (2)

Publication Number Publication Date
WO2014125408A2 WO2014125408A2 (fr) 2014-08-21
WO2014125408A3 true WO2014125408A3 (fr) 2014-12-18

Family

ID=51354636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/058881 Ceased WO2014125408A2 (fr) 2013-02-12 2014-02-10 Dérivés de 1h-pyrrolopyridinone substitués en tant qu'inhibiteurs de kinase

Country Status (1)

Country Link
WO (1) WO2014125408A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102373700B1 (ko) * 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
CN107108613B (zh) 2014-11-10 2020-02-25 基因泰克公司 布罗莫结构域抑制剂及其用途
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
JP6709792B2 (ja) 2015-01-29 2020-06-17 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
WO2017177955A1 (fr) * 2016-04-15 2017-10-19 Abbvie Inc. Inhibiteurs de bromodomaine
CN110167939B (zh) * 2017-01-11 2021-12-31 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
CN110234622B (zh) * 2017-02-06 2023-07-04 爱杜西亚药品有限公司 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法
CN110372693B (zh) * 2018-07-04 2022-05-03 清华大学 一种靶向降解bet蛋白的化合物及其应用
US20220079951A1 (en) * 2018-12-20 2022-03-17 Saint Louis University Bet inhibitors for modulating dux4 expression in fshd
AU2020242411A1 (en) * 2019-03-17 2021-11-11 Shanghai Ringene Biopharma Co., Ltd. Pyrrole amidopyridone compound, preparation method therefor and use thereof
GB201905721D0 (en) * 2019-04-24 2019-06-05 Univ Dundee Compounds
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
CN116813444A (zh) * 2023-06-28 2023-09-29 福建凯昕药业有限公司 一种1-溴-4-(1-(三氟甲基)环丙基)苯的制备方法
CN119864505B (zh) * 2024-12-20 2025-12-05 武汉亿纬储能有限公司 一种电解液及其制备方法和锂离子电池

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068728A2 (fr) * 2005-12-16 2007-06-21 Pfizer Italia Srl Pyrrolopyridinones n-substituees actives en tant qu'inhibiteurs de kinase
EP2003129A1 (fr) * 2007-06-11 2008-12-17 Nerviano Medical Sciences S.r.l. Dérivés de 1H-pyrido[3,4-B]indol-1-one et de 2,3,4,9-tétrahydro-1H-bêta-carbolin-1-one
US20100056556A1 (en) * 2007-02-27 2010-03-04 Nerviano Medical Sciences S.R.L. Isoquinolinopyrrolopyridinones active as kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068728A2 (fr) * 2005-12-16 2007-06-21 Pfizer Italia Srl Pyrrolopyridinones n-substituees actives en tant qu'inhibiteurs de kinase
US20100056556A1 (en) * 2007-02-27 2010-03-04 Nerviano Medical Sciences S.R.L. Isoquinolinopyrrolopyridinones active as kinase inhibitors
EP2003129A1 (fr) * 2007-06-11 2008-12-17 Nerviano Medical Sciences S.r.l. Dérivés de 1H-pyrido[3,4-B]indol-1-one et de 2,3,4,9-tétrahydro-1H-bêta-carbolin-1-one

Also Published As

Publication number Publication date
WO2014125408A2 (fr) 2014-08-21

Similar Documents

Publication Publication Date Title
WO2014125408A3 (fr) Dérivés de 1h-pyrrolopyridinone substitués en tant qu'inhibiteurs de kinase
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2014106800A3 (fr) Dérivés de pyrimidine à substitution 2-amino servant de composés inhibiteurs de kinase
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
EA201991884A2 (ru) Ингибиторы g12c kras
EA033689B9 (ru) Ингибиторы g12c kras
WO2014031438A3 (fr) Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MY190835A (en) Bicyclic heterrocyclic derivatives as bromodomain inhibitors
WO2014128669A3 (fr) Dérivés de benzotriazole trisubstitués à titre d'inhibiteurs de dihydroorotate oxygénase
WO2016060443A3 (fr) Composés et compositions destinés à moduler les activités kinase de l'egfr mutant
GEP20166484B (en) Protein kinase inhibitors
WO2015200680A8 (fr) Inhibiteurs de prmt5 et leurs utilisations
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
HK1211942A1 (en) Pyrazolopyrimidine compounds as kinase inhibitors
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
WO2016044641A3 (fr) Inhibiteurs de carm1 et leurs utilisations
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
NZ752587A (en) Lsd1 inhibitors and medical uses thereof
MX2019010096A (es) Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa.
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
NZ631388A (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
WO2014072930A3 (fr) Dérivés pyridine fondus, en tant qu'agents antibactériens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14751040

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14751040

Country of ref document: EP

Kind code of ref document: A2